Zurich Cantonal Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,397
| Closed | -$652K | – | 2808 |
|
|
2023
Q2 | $652K | Sell |
6,397
-100
| -2% | -$9.46K | ﹤0.01% | 1201 |
|
|
2023
Q1 | $591K | Buy |
6,497
+1,221
| +23% | +$71.6K | ﹤0.01% | 1199 |
|
|
2022
Q4 | $200K | Buy |
5,276
+791
| +18% | +$27.2K | ﹤0.01% | 1817 |
|
|
2022
Q3 | $113K | Sell |
4,485
-20
| -0.4% | -$554 | ﹤0.01% | 2126 |
|
|
2022
Q2 | $137K | Sell |
4,505
-190
| -4% | -$5.67K | ﹤0.01% | 2024 |
|
|
2022
Q1 | $154K | Sell |
4,695
-19
| -0.4% | -$564 | ﹤0.01% | 2061 |
|
|
2021
Q4 | $124K | Sell |
4,714
-1
| -0% | -$77 | ﹤0.01% | 2396 |
|
|
2021
Q3 | $474K | Buy |
4,715
+337
| +8% | +$39.5K | ﹤0.01% | 1336 |
|
|
2021
Q2 | $620K | Buy |
4,378
+1,831
| +72% | +$207K | ﹤0.01% | 1102 |
|
|
2021
Q1 | $254K | Sell |
2,547
-276
| -10% | -$32.2K | ﹤0.01% | 1651 |
|
|
2020
Q4 | $349K | Buy |
2,823
+243
| +9% | +$31.9K | ﹤0.01% | 1494 |
|
|
2020
Q3 | $251K | Hold |
2,580
| – | – | ﹤0.01% | 1444 |
|
|
2020
Q2 | $403K | Buy |
2,580
+827
| +47% | +$126K | ﹤0.01% | 1118 |
|
|
2020
Q1 | $253K | Buy |
1,753
+420
| +32% | +$81.1K | ﹤0.01% | 1113 |
|
|
2019
Q4 | $273K | Buy |
1,333
+93
| +8% | +$17K | ﹤0.01% | 1173 |
|
|
2019
Q3 | $100K | Buy |
1,240
+249
| +25% | +$21.1K | ﹤0.01% | 1621 |
|
|
2019
Q2 | $94K | Hold |
991
| – | – | ﹤0.01% | 1663 |
|
|
2019
Q1 | $85K | Buy |
991
+496
| +100% | +$41.2K | ﹤0.01% | 1677 |
|
|
2018
Q4 | $28K | Hold |
495
| – | – | ﹤0.01% | 2341 |
|
|
2018
Q3 | $40K | Buy |
+495
| New | +$34.9K | ﹤0.01% | 2271 |
|
Other funds holding RETA
Zurich Cantonal Bank's RETA Position: Q3 2023 in Review
Zurich Cantonal Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 6,397 shares — an estimated $652K sold.
Zurich Cantonal Bank first reported a position in RETA in Q3 2018 and held it in 20 quarters. The position peaked at $652K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Zurich Cantonal Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Zurich Cantonal Bank sold 6,397 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $652K.
- Zurich Cantonal Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 20 quarters.
- Zurich Cantonal Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $652K in Q2 2023.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Zurich Cantonal Bank's 13F filing for Q3 2023, filed 25 Oct 2023.